期刊
PEDIATRIC NEPHROLOGY
卷 -, 期 -, 页码 -出版社
SPRINGER
DOI: 10.1007/s00467-022-05684-1
关键词
Hyperoxaluria; Primary; Infant; Nephrocalcinosis; RNA interference; Lumasiran
资金
- Alnylam Pharmaceuticals
Lumasiran treatment demonstrated effective reduction in urinary oxalate levels and maintained safety through month 12 across all weight subgroups, with continued improvements in plasma oxalate levels and kidney stone event rates remaining low.
Background Primary hyperoxaluria type 1 (PH1) is a rare genetic disease that causes progressive kidney damage and systemic oxalosis due to hepatic overproduction of oxalate. Lumasiran demonstrated efficacy and safety in the 6-month primary analysis period of the phase 3, multinational, open-label, single-arm ILLUMINATE-B study of infants and children < 6 years old with PH1 (ClinicalTrials.gov: NCT03905694 (4/1/2019); EudraCT: 2018-004,014-17 (10/12/2018)). Outcomes in the ILLUMINATE-B extension period (EP) for patients who completed >= 12 months on study are reported here. Methods Of the 18 patients enrolled in the 6-month primary analysis period, all entered the EP and completed >= 6 additional months of lumasiran treatment (median (range) duration of total exposure, 17.8 (12.7-20.5) months). Results Lumasiran treatment was previously reported to reduce spot urinary oxalate:creatinine ratio by 72% at month 6, which was maintained at 72% at month 12; mean month 12 reductions in prespecified weight subgroups were 89%, 68%, and 71% for patients weighing < 10 kg, 10 to < 20 kg, and >= 20 kg, respectively. The mean reduction from baseline in plasma oxalate level was reported to be 32% at month 6, and this improved to 47% at month 12. Additional improvements were also seen in nephrocalcinosis grade, and kidney stone event rates remained low. The most common lumasiran-related adverse events were mild, transient injection-site reactions (3 patients (17%)). Conclusions Lumasiran treatment provided sustained reductions in urinary and plasma oxalate through month 12 across all weight subgroups, with an acceptable safety profile, in infants and young children with PH1.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据